Free Trial
Ends Tomorrow! Last Chance to Get MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:BFRIW

Biofrontera Earnings Date & Estimates

Biofrontera logo
$0.0014 0.00 (0.00%)
As of 02:22 PM Eastern

Biofrontera is estimated to report earnings on Wednesday, November 18, 2026, before market opens.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Biofrontera

Biofrontera is expected to post earnings of -$0.22 per share on revenue of $8.25 million.

Consensus Estimates

Consensus EPS
-$0.22
Expected Revenue
$8.25 million

Prepare for the Earnings Call

Biofrontera Earnings FAQ

Biofrontera (NASDAQ:BFRIW) is estimated to report earnings on Wednesday, November 18, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Biofrontera to post earnings of -$0.22 per share for the quarter.

The consensus revenue estimate for Biofrontera is $8.25 million for the quarter.

Biofrontera Earnings Headlines

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377367/0/en/biofrontera-submits-supplemental-new-drug-application-to-fda-to-expand-ameluz-red-light-pdt-to-actinic-keratoses-on-the-full-body.html
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361199/0/en/biofrontera-announces-fda-approval-of-ameluz-red-light-pdt-for-the-treatment-of-superficial-basal-cell-carcinoma.html
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
October 29 at 1:00 AM  |  Monument Traders Alliance (Ad)
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344531/0/en/biofrontera-inc-reports-strong-second-quarter-2026-financial-results-driven-by-33-revenue-growth.html
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299432/0/en/biofrontera-inc-to-participate-in-the-lytham-partners-spring-2026-investor-conference-on-may-28-2026.html
See More Biofrontera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email.

About Biofrontera

Biofrontera (NASDAQ:BFRIW) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products. The company’s principal business centers on treatments for actinic keratosis, a common precancerous skin condition caused by long-term sun exposure.

Biofrontera’s flagship product is Ameluz, a topical aminolevulinic acid hydrochloride treatment used in photodynamic therapy for actinic keratoses. The therapy is administered with the company’s BF-RhodoLED lamp, which activates the treatment on affected areas of the skin. Biofrontera markets these products primarily to dermatology practices in the United States.

Biofrontera Inc. was established as the U.S.-focused operating company of Germany-based Biofrontera AG and became a separately listed company in 2021. Its business is concentrated on the commercialization of dermatology therapies and related medical devices, while Biofrontera AG has historically been involved in the broader development and international commercialization of the group’s products. BFRIW represents Biofrontera warrants traded on Nasdaq.

View Biofrontera Profile
Earnings Tools